Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company has established itself as a global leader in virology, with revolutionary advancements in HIV treatment and prevention that have fundamentally transformed patient care. Gilead delivered the first cure for hepatitis C and continues to push boundaries in oncology and inflammatory diseases through bold scientific innovation and strategic acquisitions.
With more than 17,000 employees worldwide and operations spanning over 35 countries, Gilead combines deep scientific expertise with a relentless commitment to addressing global health challenges. The company invests billions in research and development annually, advancing a robust pipeline across virology, oncology, and inflammation therapeutic areas. Gilead's mission extends beyond medicine - the company actively works to dismantle health inequities and expand access to treatments through partnerships, pricing initiatives, and patient assistance programs globally.
